CA2192965C - Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions - Google Patents

Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions Download PDF

Info

Publication number
CA2192965C
CA2192965C CA002192965A CA2192965A CA2192965C CA 2192965 C CA2192965 C CA 2192965C CA 002192965 A CA002192965 A CA 002192965A CA 2192965 A CA2192965 A CA 2192965A CA 2192965 C CA2192965 C CA 2192965C
Authority
CA
Canada
Prior art keywords
integer
arachidonyl
ophthalmic composition
heterocyclic ring
ident
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002192965A
Other languages
English (en)
Other versions
CA2192965A1 (fr
Inventor
David W. Pate
Tomi Jarvinen
Kristiina Jarvinen
Arto Urtti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/272,532 external-priority patent/US5631297A/en
Application filed by Individual filed Critical Individual
Publication of CA2192965A1 publication Critical patent/CA2192965A1/fr
Application granted granted Critical
Publication of CA2192965C publication Critical patent/CA2192965C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des analogues d'anandamide destinés à être utilisés pour le traitement de l'hypertension intra-oculaire, des compositions ophthalmiques comprenant lesdits analogues d'anandamide et une cyclodextrine ainsi que des procédés de traitement de l'hypertension intra-oculaire à l'aide de ces composés.
CA002192965A 1994-07-11 1995-07-10 Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions Expired - Fee Related CA2192965C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/272,532 1994-07-11
US08/272,532 US5631297A (en) 1994-07-11 1994-07-11 Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US45744295A 1995-06-01 1995-06-01
US08/457,442 1995-06-01
PCT/US1995/008226 WO1996001558A1 (fr) 1994-07-11 1995-07-10 Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions

Publications (2)

Publication Number Publication Date
CA2192965A1 CA2192965A1 (fr) 1996-01-25
CA2192965C true CA2192965C (fr) 2007-12-04

Family

ID=26955582

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002192965A Expired - Fee Related CA2192965C (fr) 1994-07-11 1995-07-10 Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions

Country Status (5)

Country Link
US (1) US5977180A (fr)
EP (1) EP0777415A4 (fr)
AU (1) AU3124995A (fr)
CA (1) CA2192965C (fr)
WO (1) WO1996001558A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109087B (fi) * 1998-12-23 2002-05-31 Tomi Jaervinen Menetelmä farmaseuttisen koostumuksen valmistamiseksi
CA2410401A1 (fr) * 2000-05-23 2001-11-29 Daniele Piomelli Nouveau traitement contre la toux
WO2003097573A1 (fr) * 2002-05-16 2003-11-27 Sepracor, Inc. Amines inhibant un transporteur d'anandamide de type mammalien, et procedes d'utilisation
JP2009538827A (ja) * 2006-05-01 2009-11-12 イースタン バージニア メディカル スクール カンナビノイドおよび使用方法
BR112012031194A2 (pt) * 2010-06-08 2018-05-29 Krisani Biosciences P Ltd derivados de cisteamina e seu uso no tratamento de ehna
CN109419789B (zh) * 2017-08-31 2021-09-21 清华大学 治疗和/或预防免疫紊乱疾病的化合物及其应用
IT201700120375A1 (it) * 2017-10-24 2019-04-24 For Health Pharma S R L Soluzioni acquose stabili che comprendono PUFAs
US20250205181A1 (en) * 2021-08-04 2025-06-26 Czap Research And Development, Llc Anandamide cyclodextrin inclusion complex vehicles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649650A (en) * 1970-02-13 1972-03-14 Little Inc A Novel derivatives of tetrahydro-cannabinol
US4327028A (en) * 1978-08-17 1982-04-27 Calcol, Inc. Composition of matter
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4476140A (en) * 1983-05-16 1984-10-09 Yale University Composition and method for treatment of glaucoma
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ES2037385T3 (es) * 1988-01-14 1993-06-16 Akzo N.V. Un procedimiento de manufactura de una preparacion farmaceutica para administracion local.
CA1321192C (fr) * 1988-04-20 1993-08-10 Abdul Majid Complexes d'inclusion de cyclodextrines obtenus par agglomeration
CA2017156A1 (fr) * 1989-06-02 1990-12-02 Sotoo Asakura Preparation de la substance fr115224 pour administration parenterale
CA2031469A1 (fr) * 1989-12-28 1991-06-29 Larry A. Wheeler Utilisation de composes d'inclusion de prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire
TW200402B (fr) * 1990-08-13 1993-02-21 Senju Pharma Co
IL103932A (en) * 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same

Also Published As

Publication number Publication date
EP0777415A1 (fr) 1997-06-11
AU3124995A (en) 1996-02-09
EP0777415A4 (fr) 1999-06-16
CA2192965A1 (fr) 1996-01-25
US5977180A (en) 1999-11-02
WO1996001558A1 (fr) 1996-01-25

Similar Documents

Publication Publication Date Title
US5631297A (en) Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
US5124154A (en) Aminosteroids for ophthalmic use
Loftsson et al. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations
KR102774277B1 (ko) 안과용 활성 약학 성분 전달을 위한 고형 사이클로덱스트린 복합체의 제조
CN101491520B (zh) 局部应用的药物制剂
KR101689924B1 (ko) 고농도 올로파타딘 안과용 조성물
US5252319A (en) Aminosteroids for ophthalmic use
CA1333363C (fr) Inhibiteur de l'angiogenese contenant de la fumagilline
EP2346520B1 (fr) Curcuminoïdes et leurs métabolites pour des applications relatives aux maladies oculaires
DE69422707T2 (de) Verfahren zur verhinderung der trübung der hinteren linsenkapsel
EP2429507B1 (fr) Composition pharmaceutique sans phosphates pour le traitement du glaucome
PL173347B1 (pl) Środek przeciwalergiczny do stosowania do oczu lub nosa
US5209926A (en) Aminosteroids for ophthalmic use
CA2192965C (fr) Compositions d'analogues d'anandamide et procede de traitement de l'hypertension intra-oculaire a l'aide de telles compositions
RU2494727C2 (ru) Фармацевтическая композиция, содержащая фторхинолоновое антибиотическое лекарственное средство
HU207443B (en) Method for producing medicine preparations serving for decreasing eye pressure containing imidazole derivatives
CN1604784A (zh) 含有肝素的眼科制剂
EP0633025A1 (fr) Composition pharmaceutique contenant du 3-méthyl-1-phényl-2-pyrazolin-5-one pour le traitement des maladies ophthalmiques
CA2966592C (fr) Administration oculaire de medicaments
TWI712429B (zh) 水性醫藥組成物
WO2021101883A1 (fr) Compositions contenant du chitosane et procédés associés
JPS58500995A (ja) 緑内障治療用組成物
CN111868097B (zh) 司坦唑醇与透明质酸的缀合物
JP2714678B2 (ja) 虚血性臓器障害予防・治療剤
CA2761740A1 (fr) Composition pharmaceutique sans phosphates pour le traitement du glaucome

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed